Objective: To the expression and clinical value of immunoglobulin γ-1 heavy chain constant region (IGHG1) in skin cutaneous melanoma based on the combination of RNA-Seq expression and clinical information in The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. Methods: Wilcoxon signed-rank test and logistic regression were used to explore the relationship between IGHG1 expression and clinical parameters such as gender, stage, and lymph node. The correlation between clinicopathological characteristics and overall survival (OS) of skin cutaneous melanoma patients was estimated by Cox regression and the Kaplan-Meier method. Gene set enrichment analysis (GSEA) was conducted to analyze the potential mechanism of the IGHG1 genes in the progression of skin cutaneous melanoma. Results: Compared with normal samples, IGHG1 was significantly upregulated in skin cutaneous melanoma. The expression of IGHG1 in patients with skin cutaneous melanoma was statistically significant with T stage and clinical stage (P<0.001). Melanoma patients with higher IGHG1 expression had a better prognosis than those with lower IGHG1 expression according to Kaplan-Meier survival analysis (P<0.001). Univariate Cox analysis showed that high expression of IGHG1 could improve the prognosis of patients (P=0.002); multivariate Cox regression analysis showed that IGHG1 expression could be used as an independent indicator of prognosis in patients with skin melanoma (P=0.014). GESA showed that the highly expressed phenotypes in IGHG1 were enriched to varying degrees with various signaling pathways. Conclusion: IGHG1 expression is significantly correlated with the prognosis of patients with skin cutaneous melanoma and is involved in a great many of immunological pathways that affect the occurrence and development of the tumor.